ArticleBMC molecular and cell biology2026
Immunomodulatory effects of TAK-242 on osteogenesis of mesenchymal stem cells in acute inflammatory conditions.
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone regeneration involves a complex series of stages that need proper regulation of the acute inflammatory response. Toll-like receptor 4 (TLR4) is expressed in cells necessary for bone metabolism and modulates inflammatory conditions. However, excessive TLR4 activation can lead to immune dysregulation and decreased bone mineral deposition. This study investigates the effects of inhibiting TLR4 using TAK-242 on the osteogenesis of bone marrow-derived mesenchymal stem cells (BM-MSCs) under an acute inflammatory condition induced by lipopolysaccharide (LPS).
methodsBM-MSCs were obtained from rats, cultured, and evaluated to validate their characteristics. Subsequently, the cells were stimulated with LPS to induce an acute inflammatory model, followed by treatment with TAK-242 to assess its immunomodulatory effects on inflammatory responses, and osteogenic differentiation.
resultsTAK-242 exhibited significant anti-inflammatory effects on LPS-stimulated cells, with decreased expressions of IL-6 (p < 0.01), TNF-α (p < 0.0001), and MMP-13 (p < 0.0001) and increased expression of TGF-β (p < 0.0001) compared to LPS-only treatment cells. Notably, the TAK-242 treatment group exhibited a decrease in osteogenic differentiation compared to the LPS-only treatment group in the early stage. This was evidenced by reduced formation of mineralized nodules and decreased expression of CoL1A1 (p < 0.0001). However, RUNX-2, ALP, and OCN expression levels did not significantly reduce, indicating that TAK-242 did not impede the process of osteogenesis.
conclusionsThese findings emphasize the possible therapeutic use of TAK-242 in the field of osteoimmunology, particularly for treating inflammatory bone conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.